– Patients successfully self-managed PSVT episodes with etripamil which reduced need for ED intervention – – As in other studies, etripamil was well tolerated by patients – – Data to be featured during late breaking session at Heart Rhythm 2022 […]
Tag: Paroxysmal
EPIX Therapeutics Announces Completion of DIAMOND-AF Paroxysmal Study and First Enrollment in DIAMOND-AF II Persistent Study
SANTA CLARA, Calif., Oct. 4, 2018 /PRNewswire/ — EPIX Therapeutics, Inc., a medical device company that designs and manufactures a catheter-based system for the treatment of patients with atrial fibrillation (AFIB), today announced achievement of the enrollment goal of the DIAMOND-AF study, a […]
Milestone Pharmaceuticals Announces First Patient Randomized in the Phase 3 NODE-301 Clinical Trial Evaluating Etripamil for Termination of Paroxysmal Supraventricular Tachycardia (PSVT) Episodes
MONTREAL, Aug. 8, 2018 /PRNewswire/ — Milestone Pharmaceuticals, a clinical-stage cardiovascular company, today announced that the first patient has been randomized in its Phase 3 clinical study of etripamil. Etripamil is a new investigational, rapid-onset, short-acting calcium channel blocker administered intranasally by the […]
Recent
Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
Vensana Capital Closes $425 Million Fund III to Back Breakthrough Medical Technology Companies
Popular
- No commented posts yet